GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Equity-to-Asset

Intelligent Bio Solutions (Intelligent Bio Solutions) Equity-to-Asset : 0.37 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Intelligent Bio Solutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.28 Mil. Intelligent Bio Solutions's Total Assets for the quarter that ended in Dec. 2023 was $8.83 Mil. Therefore, Intelligent Bio Solutions's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.37.

The historical rank and industry rank for Intelligent Bio Solutions's Equity-to-Asset or its related term are showing as below:

INBS' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.03   Med: 0.45   Max: 0.94
Current: 0.37

During the past 7 years, the highest Equity to Asset Ratio of Intelligent Bio Solutions was 0.94. The lowest was -3.03. And the median was 0.45.

INBS's Equity-to-Asset is ranked worse than
79.89% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs INBS: 0.37

Intelligent Bio Solutions Equity-to-Asset Historical Data

The historical data trend for Intelligent Bio Solutions's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Bio Solutions Equity-to-Asset Chart

Intelligent Bio Solutions Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial -1.71 -2.10 0.69 0.54 0.37

Intelligent Bio Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.57 0.37 0.16 0.37

Competitive Comparison of Intelligent Bio Solutions's Equity-to-Asset

For the Medical Devices subindustry, Intelligent Bio Solutions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelligent Bio Solutions's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's Equity-to-Asset falls into.



Intelligent Bio Solutions Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Intelligent Bio Solutions's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=3.799/10.355
=0.37

Intelligent Bio Solutions's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3.28/8.827
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelligent Bio Solutions  (NAS:INBS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Intelligent Bio Solutions Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Traded in Other Exchanges
Address
57th Street, 142 West, 11th Floor, New York, NY, USA, 10019
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.
Executives
Harry Simeonidis director, officer: CEO, President 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation 10 percent owner 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins director P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg director 1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris officer: Chief Financial Officer 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd 10 percent owner LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers director 1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher director C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis director 708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd director 708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017

Intelligent Bio Solutions (Intelligent Bio Solutions) Headlines